Mayo Clinic Alix School of Medicine, Rochester, Minnesota.
Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.
Int J Radiat Oncol Biol Phys. 2022 Nov 15;114(4):684-692. doi: 10.1016/j.ijrobp.2022.07.014. Epub 2022 Jul 22.
Prostate cancer ranges from localized, low risk to metastatic, morbid disease. Although radiation therapy (RT) is commonly incorporated in the treatment of early disease or for palliation of symptomatic lesions, its role in extending survival in metastatic disease is less well-established. Here, we review the available evidence surrounding localized RT in the presence of oligometastatic disease and metastasis-directed therapy in both hormone-sensitive and hormone-resistant prostate cancer. We further outline potential future incorporation of RT as an immune-sensitizing therapy and the importance of highly sensitive imaging modalities in considering RT in metastatic disease.
前列腺癌的范围从局限性、低风险到转移性、恶性疾病不等。尽管放射治疗（RT）通常被纳入早期疾病的治疗或缓解症状性病变，但它在转移性疾病中延长生存的作用尚未得到充分确立。在这里，我们回顾了在寡转移疾病和激素敏感和激素抵抗前列腺癌中存在的局部 RT 以及针对转移灶的治疗的现有证据。我们还进一步概述了 RT 作为免疫致敏治疗的潜在未来应用，以及在考虑转移性疾病中的 RT 时高度敏感的成像方式的重要性。
